[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554110":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":32,"responsibleParty":49,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Weizmann Institute of Science","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"crohn disease patients",null,"Candidates for a medically-indicated, diagnostic colonoscopy due to suspected new-onset CD.",[13],"Other: colonoscopy procedure",{"label":15,"type":10,"description":16,"interventionNames":17},"healthy controls","healthy participants admitted for non-specific GI complaints (such as changes in bowel movements, bloating, abdominal pain) or routine screening for colorectal cancer as part of primary",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"colonoscopy procedure","Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.\n\ncolonoscopy will not be done for research purposes only .",[9,15],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Eran Elinav, Prof","CONTACT","+97289524014","Eran.Elinav@weizmann.ac.il",{"name":30,"role":26,"phone":27,"phoneExt":10,"email":31},"shimrit eliyahu miller","Shimrit.miller@weizmann.ac.il",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Emek medical center","RECRUITING","Afula","Israel","IL",{"type":40,"coordinates":41},"Point",[42,43],35.2892,32.60907,{"lat":43,"lon":42},[46],{"name":47,"role":26,"phone":10,"phoneExt":10,"email":48},"Eran Zeitan, Dr","eranzittan@clalit.org.il",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":6},"HaEmek Medical Center, Israel","100554110","decoding-the-clinical-impact-of-host-and-microbial-intestinal-proteomic-landscape-in-crohns-disease-100554110",false,"NCT06494826","Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease","Inclusion criteria - CD study group:\n\n* Age ≥ 18\n* Candidates for a medically-indicated, diagnostic colonoscopy due to suspected new-onset CD.\n* Naïve to any medical or nutritional intervention.\n\nInclusion criteria - healthy controls:\n\n• Age- and gender-matched patients to the CD group, admitted for non-specific GI complaints (such as changes in bowel movements, bloating, abdominal pain) or routine screening for colorectal cancer as part of primary prevention per clinical guidelines.\n\nExclusion Criteria - both groups:\n\n* Established diagnosis of inflammatory bowel disease (IBD) with prior treatment.\n* Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).\n* Type 1 or type 2 diabetes mellitus.\n* Past or present history of malignancy.\n* BMI \\> 30 (kg\u002Fm2)\n* Use of systemic antibiotics or probiotics 2 months prior to enrolment.\n* Use of steroids 2 months prior to enrolment (not including a short course of topical steroidal therapy).\n* Any previous major gastric or intestinal surgery.\n* Suspected or proven extensive involvement of non-ileal small intestine or colon, or significant perianal disease.\n* Significantly stricturing or penetrating (fistulizing) disease at presentation.\n* Chronic treatment with any oral\u002Fsystemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalers\u002Fcreams\u002Fointments should not be excluded from the study.\n* Primary immunodeficiency.\n* Pregnancy or breastfeeding in the last 6 months.\n* Serious medical conditions that may alter the gut microbiome composition, based on investigators judgement (for example primary immunodeficiency, autoimmune disorder, or rheumatologic disease).",true,"ALL","18 Years",{"count":64,"type":65},40,"ESTIMATED","OBSERVATIONAL","In this study, the investigators will explore our protein-based platform assessing commensals potentially contributing to features of CD, while assessing the global composition and abundance of AMPs expressed in the GI tract under specific CD-relevant clinical contexts. This would enable us to (a) identify new commensals contributing to features of CD spectrum and various sub-types; (b) uncover the mechanistic basis of dysbiosis in CD (c) utilize the pipeline to develop new theranostic for disease exacerbation, complication and treatment responses; and (d) potentially enable future exploitation of novel AMP combinations, and their respective antimicrobial capacity to counteract dysbiosis in CD.\n\nUncovering the proteomic manifestations of perturbed host-microbiome communications in CD will eventually enable the development and validation of clinical non-invasive surrogate markers, mechanistically determine causative drivers of CD, and potentially facilitate the development of novel therapeutic interventions.",[69],"Crohn Disease","2026-06-09",{"date":72,"type":73},"2026-06-11","ACTUAL",{"date":75,"type":73},"2024-05-01",{"date":77,"type":65},"2029-05",{"name":5,"class":6},1]